创新,优先级和可持续性:制药服务的当代困境
Claudia Garcia Serpa Osorio-de-Castro1, Tatiana de Jesus Nascimento Ferreira1, Claudia Du Bocage Santos-Pinto2
1Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz. R. Leopoldo Bulhões 1480, Manguinhos. 21041-210 Rio de Janeiro RJ Brasil. claudiaosorio.soc@gmail.com.
专注于制药创新而不是必需药物的医疗系统的可持续性. 优先考虑创新需要强有力的证据和系统能力,需要预算影响分析和监管改进.
科学领域:
- 医疗保健服务研究 医疗服务研究
- 制药政策 制药政策
- 卫生系统管理管理卫生系统管理
背景情况:
- 最近的文献强调了制药服务中的技术,资金,获取不平等以及监管问题.
- 医药服务领域的创新日益受到重视.
研究的目的:
- 分析优先考虑创新而不是基本药物的影响.
- 检查这一重点对卫生系统可持续性的影响.
- 确定有效制药服务组织的策略.
主要方法:
- 文献审查和对制药服务当前趋势的批判性分析.
- 讨论创新实施的卫生系统要求.
- 探索政策和监管解决方案.
主要成果:
- 优先考虑一流的创新可能与健康优先事项或既定标准不一致.
- 创新的有效实施取决于结构,财务和劳动力能力.
- 预算影响分析和改进的监管框架至关重要.
结论:
- 过度强调创新可能会危及基本药物的可用性和卫生系统的可持续性.
- 重组制药服务需要解决创新和基本药物的优先级之间的紧张关系.
- 加强卫生系统对于整合有益的创新至关重要.
相关概念视频
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Introduction To Health Care Delivery System
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence


